Cargando…
Protective Efficacy of a Mucosal Influenza Vaccine Formulation Based on the Recombinant Nucleoprotein Co-Administered with a TLR2/6 Agonist BPPcysMPEG
Current influenza vaccines target highly variable surface glycoproteins; thus, mismatches between vaccine strains and circulating strains often diminish vaccine protection. For this reason, there is still a critical need to develop effective influenza vaccines able to protect also against the drift...
Autores principales: | Sanchez, Maria Victoria, Ebensen, Thomas, Schulze, Kai, Cargnelutti, Diego Esteban, Scodeller, Eduardo A., Guzmán, Carlos A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10057018/ https://www.ncbi.nlm.nih.gov/pubmed/36986773 http://dx.doi.org/10.3390/pharmaceutics15030912 |
Ejemplares similares
-
Intranasal Delivery of Influenza rNP Adjuvanted with c-di-AMP Induces Strong Humoral and Cellular Immune Responses and Provides Protection against Virus Challenge
por: Sanchez, Maria Victoria, et al.
Publicado: (2014) -
Pulmonary Application of Novel Antigen-Loaded Chitosan Nano-Particles Co-Administered with the Mucosal Adjuvant C-Di-AMP Resulted in Enhanced Immune Stimulation and Dose Sparing Capacity
por: Ebensen, Thomas, et al.
Publicado: (2023) -
Self-Amplifying Pestivirus Replicon RNA Encoding Influenza Virus Nucleoprotein and Hemagglutinin Promote Humoral and Cellular Immune Responses in Pigs
por: Démoulins, Thomas, et al.
Publicado: (2021) -
Formulated Phospholipids as Non-Canonical TLR4 Agonists
por: Liang, Hong, et al.
Publicado: (2022) -
The MPEG handbook
por: Watkinson, John
Publicado: (2004)